(NASDAQ: MYGN) Myriad Genetics's forecast annual revenue growth rate of 3.04% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.62%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 70.6%.
Myriad Genetics's revenue in 2023 is $661,400,000.On average, 1 Wall Street analysts forecast MYGN's revenue for 2023 to be $55,459,543,670, with the lowest MYGN revenue forecast at $55,459,543,670, and the highest MYGN revenue forecast at $55,459,543,670. On average, 4 Wall Street analysts forecast MYGN's revenue for 2023 to be $60,255,286,969, with the lowest MYGN revenue forecast at $60,037,954,274, and the highest MYGN revenue forecast at $60,475,536,881.
In 2024, MYGN is forecast to generate $65,284,893,860 in revenue, with the lowest revenue forecast at $64,632,571,642 and the highest revenue forecast at $65,937,216,079.